Want to see IN:MANORG full AI Analyst Report?
Top Page
Mangalam Organics Ltd
(MANORG)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹484.00
▼(-8.68% Downside)
Action:Reiterated
Date:06/01/26
Technical strength (price above major moving averages with positive MACD) supports the score, but overall fundamentals are constrained by negative operating/free cash flow and rising leverage despite the earnings recovery. Valuation is moderate and does not materially offset the cash-flow and balance-sheet risk.
Positive Factors
Terpene-focused specialty chemicals
Specialization in terpene-based specialty chemicals serving fragrances, personal care, pharmaceuticals and industrial markets creates durable demand diversification. Technical know-how in turpentine derivatives supports a barrier to entry and repeat B2B sales across steady end-markets.
Negative Factors
Rising leverage
Material increase in total debt over two years raises financial risk: higher interest burden and weaker headroom for capex or downturn responses. Elevated leverage narrows flexibility, increases refinancing and covenant exposure, and pressures cash flows if margins slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Terpene-focused specialty chemicals
Specialization in terpene-based specialty chemicals serving fragrances, personal care, pharmaceuticals and industrial markets creates durable demand diversification. Technical know-how in turpentine derivatives supports a barrier to entry and repeat B2B sales across steady end-markets.
Read all positive factors
Mangalam Organics Ltd (MANORG) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.88B
Dividend YieldN/A
Average Volume (3M)489.00
Price to Earnings (P/E)18.9
Beta (1Y)1.25
Revenue Growth17.28%
EPS Growth-11.76%
CountryIN
Employees349
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)23.86
Shares Outstanding8,564,440
10 Day Avg. Volume561
30 Day Avg. Volume489
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.00
Price to Sales (P/S)0.51
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mangalam Organics Ltd Business Overview & Revenue Model
Company Description
Mangalam Organics Limited, together with its subsidiaries, manufactures and sells chemicals for the industrial and consumer markets in India and internationally. The company offers terpene products, including camphor, camphene, dipentene, isoborny...
How the Company Makes Money
Mangalam Organics makes money primarily by manufacturing and selling terpene and turpentine-derived specialty chemicals to business customers. Its revenue is largely generated from (1) sale of core terpene chemicals (commonly including products su...
Mangalam Organics Ltd Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
48
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.55B | 6.23B | 5.30B | 4.94B | 4.93B | 4.91B |
| Gross Profit | 2.42B | 2.17B | 2.57B | 1.13B | 701.20M | 1.47B |
| EBITDA | 857.00M | 890.69M | 589.13M | 390.38M | -24.27M | 924.25M |
| Net Income | 207.96M | 257.56M | 125.97M | 42.86M | -272.25M | 537.43M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 7.40B | 6.24B | 4.85B | 5.06B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 25.91M | 25.91M | 189.27M | 20.19M | 12.79M | 12.78M |
| Total Debt | 0.00 | 3.59B | 2.72B | 1.73B | 1.90B | 2.12B |
| Total Liabilities | -3.19B | 4.21B | 3.30B | 2.05B | 2.30B | 2.56B |
| Stockholders Equity | 3.19B | 3.19B | 2.93B | 2.81B | 2.76B | 3.04B |
Cash Flow | ||||||
| Free Cash Flow | -769.42M | -907.41M | -751.15M | 327.48M | 361.57M | -1.84B |
| Operating Cash Flow | -281.34M | -272.47M | -78.44M | 727.23M | 769.23M | -841.04M |
| Investing Cash Flow | -381.05M | -600.78M | -670.47M | -395.09M | -407.80M | -995.25M |
| Financing Cash Flow | 673.44M | 879.76M | 736.26M | -325.52M | -355.77M | 1.83B |
Mangalam Organics Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹7.07B | 24.86 | ― | 3.70% | 17.43% | 10.63% | |
61 Neutral | ₹3.88B | 18.86 | ― | ― | 17.28% | -11.76% | |
58 Neutral | ₹6.84B | 12.29 | ― | 1.23% | 1.86% | -2.21% | |
57 Neutral | ₹27.54B | 18.48 | ― | 0.09% | 19.47% | 11.49% | |
56 Neutral | ₹5.45B | 30.32 | ― | 0.25% | 25.22% | 20.39% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹9.01B | 61.99 | ― | 1.07% | 0.14% | 58.54% |
* General Sector Average
IN:MANORG
Mangalam Organics Ltd
449.90
-143.40
-24.17%
IN:AARTISURF
Aarti Surfactants Ltd.
659.70
181.43
37.93%
IN:CHEMCON
Chemcon Speciality Chemicals Ltd
192.00
-24.25
-11.21%
IN:FAIRCHEMOR
Fairchem Organics Ltd
701.20
-136.30
-16.28%
IN:JAYAGROGN
Jayant Agro-Organics Limited
223.10
-17.69
-7.35%
IN:ROSSARI
Rossari Biotech Ltd
501.95
-122.90
-19.67%
Mangalam Organics Ltd Corporate Events
Mangalam Organics sets AGM date and overhauls statutory auditor line-up
Jul 28, 2026
Mangalam Organics Ltd’s board has approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following review by the audit committee, marking a key regulatory milestone in its quarterly reportin...
Mangalam Organics Confirms SEBI-Compliant Dematerialisation for June Quarter
Jul 4, 2026
Mangalam Organics Ltd, an ISO 9001/14001/45001 certified camphor and organics producer with manufacturing operations in Raigad, Maharashtra, has its equity shares listed on BSE and NSE and uses MUFG Intime India Private Limited as its registrar an...
Mangalam Organics pegs Khopoli fire loss at Rs 12.58 crore, awaits insurance payout
Jul 3, 2026
Mangalam Organics Ltd has updated exchanges on the fallout of a fire that struck its Camphor Plant I at Khopoli on July 16, 2025, confirming that an insurance surveyor has completed the loss assessment. The incident affected the company’s ke...
CRISIL Upgrades Mangalam Organics’ Credit Profile, Rates Subsidiary for First Time
Jul 1, 2026
Mangalam Organics Ltd has reported that CRISIL Ratings has reviewed and upgraded the credit profile of its bank facilities totaling Rs. 397 crore, shifting the long-term rating to CRISIL BBB+/Stable from a watch with developing implications and re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.